COMPANY

atai Therapeutics, Inc.

HQ: New York, NY source

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $2.73M (NIH grant 5UG3DA064403-02, continuation, notice Jul 6, 2026). NIH RePORTER 5UG3DA064403-02 (Jul 6, 2026)
Evidence (1 event)
- Jul 6, 2026 · NIH RePORTER 5UG3DA064403-02
  Organization: ATAI THERAPEUTICS, INC.; City/State: NEW YORK, NY; Project number: 5UG3DA064403-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 2733774; Administering IC: National Institute on Drug Abuse; Project title: Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals